Endoscopic cryo-ablation company CSA Medical has raised $6.6 million in a new financing round, according to an SEC filing.
The Baltimore, Md.-based company’s main product is the TruFreeze spray cryotherapy device, designed to deliver super-cold liquid nitrogen via catheter to ablate unwanted tissue, according to CSA.
The company’s latest round had 26 unlisted investors, with CSA acquiring all but $13,000 of the funds they were looking for, according to an SEC filing.
While no investors were named for the most recent round, Ascension Ventures, SC Life Services, Intersouth Partners, First Analysis, Rose Park Advisors and Blue Heron Capital are listed as company investors according to the company’s site.
The Maryland company raised approximately $3 million in a closed round in April, in which it was seeking $4 million. The company raised $16 million in a Series C round in 2013, led by Ascension Ventures, that it said it planned to use to expand its R&D footprint in Lexington, Mass.